Natixis lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 71.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,449 shares of the medical instruments supplier’s stock after purchasing an additional 3,531 shares during the period. Natixis’ holdings in West Pharmaceutical Services were worth $1,988,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Cetera Investment Advisers raised its position in shares of West Pharmaceutical Services by 4.4% in the first quarter. Cetera Investment Advisers now owns 4,864 shares of the medical instruments supplier’s stock valued at $1,998,000 after purchasing an additional 207 shares during the period. Moors & Cabot Inc. grew its position in shares of West Pharmaceutical Services by 54.4% in the first quarter. Moors & Cabot Inc. now owns 849 shares of the medical instruments supplier’s stock valued at $349,000 after purchasing an additional 299 shares in the last quarter. National Pension Service raised its stake in shares of West Pharmaceutical Services by 0.4% during the 1st quarter. National Pension Service now owns 103,190 shares of the medical instruments supplier’s stock valued at $42,381,000 after purchasing an additional 394 shares during the period. Vanguard Group Inc. lifted its holdings in West Pharmaceutical Services by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,716,312 shares of the medical instruments supplier’s stock worth $3,579,876,000 after purchasing an additional 82,459 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its stake in West Pharmaceutical Services by 152.8% in the 1st quarter. Baird Financial Group Inc. now owns 4,262 shares of the medical instruments supplier’s stock worth $1,751,000 after purchasing an additional 2,576 shares during the period. Institutional investors own 91.51% of the company’s stock.
Insider Activity at West Pharmaceutical Services
In other West Pharmaceutical Services news, Director Thomas W. Hofmann sold 1,212 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $365.57, for a total value of $443,070.84. Following the transaction, the director now directly owns 43,616 shares of the company’s stock, valued at approximately $15,944,701.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Eric Mark Green sold 44,000 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $363.10, for a total value of $15,976,400.00. Following the sale, the chief executive officer now directly owns 134,574 shares of the company’s stock, valued at $48,863,819.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas W. Hofmann sold 1,212 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $365.57, for a total value of $443,070.84. Following the transaction, the director now directly owns 43,616 shares of the company’s stock, valued at approximately $15,944,701.12. The disclosure for this sale can be found here. Insiders sold 67,244 shares of company stock worth $24,454,553 in the last ninety days. 1.13% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
West Pharmaceutical Services Price Performance
Shares of West Pharmaceutical Services stock traded up $4.76 during trading on Monday, hitting $353.04. 87,999 shares of the stock traded hands, compared to its average volume of 513,828. The stock has a market cap of $26.21 billion, a price-to-earnings ratio of 48.23, a PEG ratio of 7.18 and a beta of 1.10. The company has a quick ratio of 2.79, a current ratio of 3.62 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $206.19 and a 52 week high of $376.72. The firm’s fifty day moving average is $354.22 and its 200-day moving average is $302.63.
West Pharmaceutical Services (NYSE:WST – Get Rating) last issued its quarterly earnings results on Thursday, April 27th. The medical instruments supplier reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.31. West Pharmaceutical Services had a net margin of 19.15% and a return on equity of 24.14%. The business had revenue of $716.60 million for the quarter, compared to analysts’ expectations of $697.28 million. During the same period last year, the business earned $2.30 earnings per share. The business’s quarterly revenue was down .5% on a year-over-year basis. Research analysts expect that West Pharmaceutical Services, Inc. will post 7.68 EPS for the current fiscal year.
West Pharmaceutical Services Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 2nd. Stockholders of record on Wednesday, July 26th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Tuesday, July 25th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.44%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.
Featured Stories
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Can Cardinal Health Fly Higher In 2023?
- DraftKings Stock, Is There Royally Good Upside Ahead?
- Disney Stock Could Double: Return To Historical Performance
- For AI Exposure, Try Global Artificial Intelligence ETF
- 3 Penny Stocks The Insiders Are BuyingÂ
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
